Handelsavisen
prelaunch
Companies ›Healthcare ›204840.KQ
20
204840.KQ — KOSDAQ Biotechnology & Medical Research

204840.Kq

$890,00
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
0,8 %
ROE
0,1 %
Net margin
0,0 %
Debt / equity
0,94
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

The company operates in the healthcare diagnostics segment, providing products and services related to medical testing and diagnostic solutions.

Business. The company operates in the healthcare diagnostics segment, providing products and services related to medical testing and diagnostic solutions.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
0,1 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 204840.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 204840.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the healthcare diagnostics segment, providing products and services related to medical testing and diagnostic solutions.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 0.94, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.01, suggesting limited short-term liquidity cushion. The company's cash and equivalents amount to 3,036,108,450 KRW, but this is insufficient to cover its long-term debt of 18,732,956,520 KRW, resulting in a net cash position that is negative after subtracting total debt.

    Profitability metrics are weak, with a return on equity of 0.06% and a return on assets of 0.03%. These figures are below the typical thresholds for industry-leading performance and suggest that the company is not generating strong returns relative to its equity and asset base.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial reporting, with no material geographic diversification provided in the available data. This lack of segment and geographic diversification increases exposure to sector-specific and regional risks.

    The company's growth trajectory is not clearly defined in the available data, with no specific numeric deltas provided for the current or next fiscal year. However, the negative operating and free cash flows suggest that the company is not currently generating sufficient cash to sustain operations without external financing.

    The company's risk profile includes medium liquidity risk, with a current ratio barely above 1.0, and a low dilution risk, as there is no indication of near-term share issuance or dilution pressure. The negative net cash position after subtracting total debt is a key flag in the risk assessment.

    Recent events and filings have not been disclosed in the available data, so no specific recent developments can be cited. The company's financial performance and risk profile suggest a need for close monitoring of its liquidity and capital structure.

    Key takeaways
    • The company has a moderate debt-to-equity ratio of 0.94, indicating a balanced but not overly leveraged capital structure.
    • Return on equity and return on assets are very low at 0.06% and 0.03%, respectively, suggesting weak profitability.
    • The company's liquidity position is fragile, with a current ratio of 1.01 and a negative net cash position after subtracting total debt.
    • There is no indication of geographic or segment diversification, increasing exposure to sector-specific and regional risks.
    • The company is not generating positive operating or free cash flows, which may necessitate external financing to sustain operations.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $890,00
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $19.92B
    Net cashⓘ
    -$15.70B
    Current ratioⓘ
    1.0
    Debt / equityⓘ
    0.9
    ROAⓘ
    0.0%
    ROEⓘ
    0.1%
    Cash conversionⓘ
    -9001.0%
    CapEx / revenueⓘ
    -9.1%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin0,8 %Above P75
    Net Margin0,0 %Above P75
    ROE0,1 %Above median
    Capex / Rev-9,1 %Above median
    D/E0,94Bottom quartile
    Cash Conv-90,01Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 204840.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    204840.KQCanonical
    KOSDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage